

Pur/09


RAW SEQUENCE LISTING DATE: 03/21/2002 PATENT APPLICATION: US/09/831,744 TIME: 18:35:51

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\03212002\I831744.raw

```
3 <110> APPLICANT: Analytica Ltd
     5 <120> TITLE OF INVENTION: PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER
      7 <130> FILE REFERENCE: 2404732/EJH
      9 <140> CURRENT APPLICATION NUMBER: US 09/831,744
C--> 10 <141> CURRENT FILING DATE: 2002-01-25
     12 <150> PRIOR APPLICATION NUMBER: US 60/108,254
     13 <151> PRIOR FILING DATE: 1998-11-12
     15 <160> NUMBER OF SEQ ID NOS: 45
     17 <170> SOFTWARE: PatentIn version 3.0
     19 <210> SEQ ID NO: 1
     20 <211> LENGTH: 202
     21 <212> TYPE: PRT
     22 <213> ORGANISM: Notechis scutatus
     24 <400> SEQUENCE: 1
     25 Met Lys Ser Leu Gln Ile Ile Cys Leu Leu Phe Val Leu Val Ala Arg
                                            10
     28 Gly Ser Cys His Ser Cys Glu Ile Cys His Asn Leu Gly Arg Asp Cys
                                        25
    31 Glu Thr Glu Glu Ala Glu Glu Cys Ala Ser Pro Glu Asp Gln Cys Gly
                                    40
     34 Thr Val Leu Met Glu Val Ser Ser Ala Pro Ile Ser Phe Arg Ser Ile
                                55
     37 His Arg Asn Cys Phe Ser Ser Leu Cys Lys Leu Glu Arg Phe Asp
                            70
                                                75
     40 Ile Asn Ile Gly His Asp Ser Tyr Leu Arg Gly Arg Ile His Cys Cys
     43 Asp Glu Ala Arg Cys Glu Ala Gln Gln Phe Pro Gly Leu Pro Leu Ser
    46 Phe Pro Asn Gly Tyr His Cys Pro Gly Ile Leu Gly Val Phe Ser Val
    47
                                    120
    49 Asp Ser Ser Glu His Glu Ala Ile Cys Arg Gly Thr Glu Thr Lys Cys
                                135
    52 Ile Asn Leu Ala Gly Phe Arg Lys Glu Arg Phe Pro Gly Asp Ile Ala
                            150
                                                155
     55 Tyr Asn Ile Lys Gly Cys Thr Ser Ser Cys Pro Glu Leu Arg Leu Ser
                        165
                                            170
    58 Asn Arg Thr His Glu Glu Asp Arg Asn Gly Leu Ile Lys Val Glu Cys
                   180
                                        185
    61 Thr Asp Ala Ser Lys Ile Thr Pro Ser Glu
                195
    64 <210> SEQ ID NO: 2
    65 <211> LENGTH: 202
```

66 <212> TYPE: PRT



PATENT APPLICATION: US/09/831,744

DATE: 03/21/2002 TIME: 18:35:51

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\03212002\1831744.raw

```
67 <213> ORGANISM: Oxyuranus scutellatus
69 <400> SEQUENCE: 2
70 Met Ile Ser Leu Gln Ile Ile Cys Phe Leu Phe Val Leu Val Ala Arg
73 Gly Ser Cys His Ser Cys Glu Ile Cys Arg Asn Phe Gly Lys Asp Cys
               20
                                   25
76 Glu Ser Glu Glu Ala Glu Glu Cys Ala Ser Pro Glu Asp Gln Cys Gly
79 Thr Val Leu Leu Glu Ile Ser Ser Ala Pro Ile Ser Phe Arg Ser Ile
82 His Arg Asn Cys Phe Ser Ser Leu Cys Lys Leu Glu His Phe Asp
                       70
                                           75
85 Ile Asn Ile Gly His Asp Ser Tyr Val Arg Gly Arg Ile His Cys Cys
88 Asp Glu Glu Arg Cys Glu Ala Gln Gln Phe Pro Gly Leu Pro Pro Ser
               100
                                   105
91 Leu Pro Asn Gly Tyr His Cys Pro Gly Ile Leu Gly Ala Phe Ser Val
                               120
94 Asp Ser Ser Glu His Glu Ala Ile Cys Arg Gly Thr Glu Thr Lys Cys
      130
                           135
                                               140
97 Ile Asn Leu Ala Gly Phe Arg Lys Glu Arg Tyr Pro Val Asp Ile Ala
100 Tyr Asn Ile Thr Gly Cys Thr Ser Ser Cys Pro Glu Leu Lys Leu Ser
101
                    165
                                        170
103 Asn Arg Thr His Ala Glu Arg Arg Asn Ala Leu Ile Thr Leu Asp Cys
104
                180
                                    185
106 Thr Asp Ala Ser Lys Ile Ala Pro Ser Glu
107
           195
109 <210> SEQ ID NO: 3
110 <211> LENGTH: 609
111 <212> TYPE: DNA
112 <213> ORGANISM: Oxyuranus microlepidotus
114 <220> FEATURE:
115 <221> NAME/KEY: CDS
116 <222> LOCATION: (1)..(606)
118 <400> SEQUENCE: 3
119 atg aaa too cta cag atc atc tgt cot ctt ttc gtt ttg gta goc aga
                                                                           48
120 Met Lys Ser Leu Gln Ile Ile Cys Pro Leu Phe Val Leu Val Ala Arg
123 gga agc tgt cgc tca tgt gaa att tgt cac aat ttt gga aaa gat tgc
                                                                           96
124 Gly Ser Cys Arg Ser Cys Glu Ile Cys His Asn Phe Gly Lys Asp Cys
                20
                                    25
127 gag agt gag gag gaa gag gaa tgt gcc tct cca gaa gat caa tgt ggc
                                                                          144
128 Glu Ser Glu Glu Ala Glu Cys Ala Ser Pro Glu Asp Gln Cys Gly
           35
                                40
131 aca gtg ttg ctg gag att tca tca gca cct att tcc ttc cga tcc att
                                                                          192
132 Thr Val Leu Leu Glu Ile Ser Ser Ala Pro Ile Ser Phe Arg Ser Ile
                            55
135 cat agg aac tgt ttc tca tcc agc ctc tqc aaa ctt qaa cac ttt qat
                                                                          240
```



PATENT APPLICATION: US/09/831,744

DATE: 03/21/2002 TIME: 18:35:51

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\03212002\1831744.raw

	•	_	_	_	_,	_	_	_	_	_	_	_				_	
		Arg	Asn	Cys	Phe		ser	Ser	Leu	Cys	_	Leu	GLu	His	Pne		
137						70					75					80	
139	ata	aat	att	gga	cat	gat	tcc	tat	gtg	aga	gga	aga	atc	cac	tgt	tgt	288
140	Ile	Asn	Ile	Gly	His	Asp	Ser	Tyr	Val	Arg	Gly	Arg	Ile	His	Cys	Cys	
141					85					90					95		
143	gat	gaa	gaa	aσσ	tgt	αaa	αca	caq	caa	t.t.t.	cct.	σσα	cta	ccc	ctc	tee	336
					Cys												550
145	пор	OLU	014	100	CyD	OIU	mru	0111	105	1110	110	CLY	LCu	110	шеи	061	
																	204
					tac												384
	Pne	Pro		GLĀ	\mathtt{Tyr}	His	Cys		GLY	IIе	Leu	GTĀ		Phe	ser	Val	
149			115					120					125				
151	gac	agc	tct	gaa	cat	gaa	gct	att	tgc	aga	gga	acc	gaa	acc	aaa	tgc	432
152	Asp	Ser	Ser	Glu	His	Glu	Ala	Ile	Cys	Arg	Gly	Thr	Glu	Thr	Lys	Cys	
153		130					135					140					
155	att	aac	ctt	aca	gga	ttc	aga	aaa	qaa	aσa	tat	cct	qta	gac	atc	act	480
					Ğĺy												
	145				U -1	150	9	-1-	0_4	5	155		,			160	
		22+	2+0		~~+		20+	+ a+	+	+~+		~~~	a+a		++~		5 00
					ggt	_				_		-	_	_	_	-	528
	Tyr	Asn	тте	ьys	Gly	Cys	Thr	ser	ser	_	Pro	GIU	Leu	ьys		ser	
162					165					170					175	•	
164	aat	aga	act	cac	gaa	gaa	cgt	aga	aat	gat	cta	ata	aca	ctt	gaa	tgt	576
165	Asn	Arg	Thr	His	Glu	Glu	Arg	Arg	Asn	Asp	Leu	Ile	Thr	Leu	Glu	Cys	
166				180					185					190			
168	aca	gat	qcc	tcc	aaa	att	aca	cct	tcc	qaa	taa						609
		_	_		Lys					-							
			195		_			200									
170	~21 <i>t</i>	- اب وا	195	NO.	_			200									
170 172			EQ II		: 4			200									
170 172 173	<21	l> Li	EQ II ENGTI	1: 20	: 4			200									
170 172 173 174	<213 <213	l> Li 2> Ti	EQ II ENGTI YPE:	i: 20	- : 4)2					•							
170 172 173 174 175	<213 <213 <213	l> L1 2> T1 3> O1	EQ II ENGTI YPE: RGANI	H: 20 PRT ISM:	- : 4)2 Oxyt				lepid	•	5						
170 172 173 174 175	<213 <213 <213	l> L1 2> T1 3> O1	EQ II ENGTI YPE:	H: 20 PRT ISM:	- : 4)2 Oxyt				lepid	•	5						
170 172 173 174 175 177	<213 <213 <213 <400	l> Li 2> Ti 3> Oi 0> Si	EQ II ENGTI YPE: RGANI EQUEN	H: 20 PRT ISM: NCE:	- : 4)2 Oxyt	ıranı	ıs mi	Lcrol	_	lotus		Val	Leu	Val	Ala	Arg	
170 172 173 174 175 177	<213 <213 <213 <400 Met	l> Li 2> Ti 3> Oi 0> Si	EQ II ENGTI YPE: RGANI EQUEN	H: 20 PRT ISM: NCE:	- : 4)2 Oxyu 4	ıranı	ıs mi	Lcrol	_	lotus		Val	Leu	Val	Ala 15	Arg	
170 172 173 174 175 177 178 179	<213 <213 <213 <400 Met 1	l> L1 2> T1 3> O1 0> S1 Lys	EQ II ENGTI YPE: RGANI EQUEN	H: 20 PRT ISM: NCE: Leu	- : 4)2 Oxyu 4 Gln 5	ıranı Ile	ıs mi Ile	Cys	Pro	lotus Leu 10	Phe				15	_	
170 172 173 174 175 177 178 179 181	<213 <213 <213 <400 Met 1	l> L1 2> T1 3> O1 0> S1 Lys	EQ II ENGTI YPE: RGANI EQUEN	H: 20 PRT ISM: NCE: Leu Arg	: 4 D2 Oxyu 4 Gln	ıranı Ile	ıs mi Ile	Cys	Pro Cys	lotus Leu 10	Phe			Lys	15	_	
170 172 173 174 175 177 178 179 181 182	<21: <21: <21: <400 Met 1 Gly	l> Li 2> Ti 3> Oi 0> Si Lys Ser	EQ II ENGTH YPE: RGANI EQUEN Ser	H: 20 PRT ISM: NCE: Leu Arg 20	Oxyu Oxyu 4 Gln 5 Ser	ıranı Ile Cys	ıs mi Ile Glu	icrol Cys Ile	Pro Cys 25	lotus Leu 10 His	Phe Asn	Phe	Gly	Lys 30	15 Asp	Cys	
170 172 173 174 175 177 178 179 181 182 184	<21: <21: <21: <400 Met 1 Gly	l> Li 2> Ti 3> Oi 0> Si Lys Ser	EQ II ENGTH YPE: RGANI EQUEN Ser Cys	H: 20 PRT ISM: NCE: Leu Arg 20	- : 4)2 Oxyu 4 Gln 5	ıranı Ile Cys	ıs mi Ile Glu	Cys Ile Cys	Pro Cys 25	lotus Leu 10 His	Phe Asn	Phe	Gly Asp	Lys 30	15 Asp	Cys	
170 172 173 174 175 177 178 179 181 182 184 185	<21: <21: <21: <400 Met 1 Gly	1> L1 2> TY 3> O1 0> S1 Lys Ser	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35	H: 20 PRT ISM: ICE: Leu Arg 20 Glu	Oxyu 4 Gln 5 Ser	ıranı Ile Cys Glu	ıs mi Ile Glu Glu	Cys Ile Cys 40	Pro Cys 25 Ala	Leu 10 His Ser	Phe Asn Pro	Phe Glu	Gly Asp 45	Lys 30 Gln	15 Asp Cys	Cys	
170 172 173 174 175 177 178 179 181 182 184 185	<21: <21: <21: <400 Met 1 Gly	1> L1 2> T3 3> O1 0> S1 Lys Ser Ser	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35	H: 20 PRT ISM: ICE: Leu Arg 20 Glu	Oxyu Oxyu 4 Gln 5 Ser	ıranı Ile Cys Glu	ıs mi Ile Glu Glu Ser	Cys Ile Cys 40	Pro Cys 25 Ala	Leu 10 His Ser	Phe Asn Pro	Phe Glu Ser	Gly Asp 45	Lys 30 Gln	15 Asp Cys	Cys	
170 172 173 174 175 177 178 179 181 182 184 185 187	<21: <21: <20: <400 Met 1 Gly Glu	1> L1 2> T: 3> OI 0> SI Lys Ser Ser Val 50	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu	H: 20 PRT ISM: NCE: Leu Arg 20 Glu Leu	Oxyu 4 Gln 5 Ser Ala	ıranı Ile Cys Glu Ile	ıs mi Ile Glu Glu Ser 55	Cys Ile Cys 40 Ser	Pro Cys 25 Ala Ala	Leu 10 His Ser	Phe Asn Pro Ile	Phe Glu Ser 60	Gly Asp 45 Phe	Lys 30 Gln Arg	15 Asp Cys Ser	Cys Gly Ile	
170 172 173 174 175 177 178 179 181 182 184 185 187 188	<211 <211 <400 Met 1 Gly Glu Thr	1> L1 2> T: 3> OI 0> SI Lys Ser Ser Val 50	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu	H: 20 PRT ISM: NCE: Leu Arg 20 Glu Leu	Oxyu 4 Gln 5 Ser	ıranı Ile Cys Glu Ile	ıs mi Ile Glu Glu Ser 55	Cys Ile Cys 40 Ser	Pro Cys 25 Ala Ala	Leu 10 His Ser	Phe Asn Pro Ile	Phe Glu Ser 60	Gly Asp 45 Phe	Lys 30 Gln Arg	15 Asp Cys Ser	Cys Gly Ile	
170 172 173 174 175 177 178 179 181 182 184 185 187 188 190	<213 <213 <400 Met 1 Gly Glu Thr	1> Li 2> Ti 3> Oi 0> Si Lys Ser Ser Val 50 Arg	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn	H: 20 PRT ISM: ICE: Leu Arg 20 Glu Leu	Oxyu 4 Gln 5 Ser Ala Glu Phe	Iranu Ile Cys Glu Ile Ser 70	Is mi Ile Glu Glu Ser 55 Ser	Cys Ile Cys 40 Ser	Pro Cys 25 Ala Ala Leu	Leu 10 His Ser Pro	Phe Asn Pro Ile Lys 75	Phe Glu Ser 60 Leu	Gly Asp 45 Phe Glu	Lys 30 Gln Arg	15 Asp Cys Ser Phe	Cys Gly Ile Asp 80	
170 172 173 174 175 177 178 179 181 182 184 185 187 188 190	<213 <213 <400 Met 1 Gly Glu Thr	1> Li 2> Ti 3> Oi 0> Si Lys Ser Ser Val 50 Arg	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn	H: 20 PRT ISM: ICE: Leu Arg 20 Glu Leu	Oxyu 4 Gln 5 Ser Ala	Iranu Ile Cys Glu Ile Ser 70	Is mi Ile Glu Glu Ser 55 Ser	Cys Ile Cys 40 Ser	Pro Cys 25 Ala Ala Leu	Leu 10 His Ser Pro	Phe Asn Pro Ile Lys 75	Phe Glu Ser 60 Leu	Gly Asp 45 Phe Glu	Lys 30 Gln Arg	15 Asp Cys Ser Phe	Cys Gly Ile Asp 80	
170 172 173 174 175 177 178 179 181 182 184 185 187 188 190	<213 <213 <400 Met 1 Gly Glu Thr	1> Li 2> Ti 3> Oi 0> Si Lys Ser Ser Val 50 Arg	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn	H: 20 PRT ISM: ICE: Leu Arg 20 Glu Leu	Oxyu 4 Gln 5 Ser Ala Glu Phe	Iranu Ile Cys Glu Ile Ser 70	Is mi Ile Glu Glu Ser 55 Ser	Cys Ile Cys 40 Ser	Pro Cys 25 Ala Ala Leu	Leu 10 His Ser Pro	Phe Asn Pro Ile Lys 75	Phe Glu Ser 60 Leu	Gly Asp 45 Phe Glu	Lys 30 Gln Arg	15 Asp Cys Ser Phe	Cys Gly Ile Asp 80	
170 172 173 174 175 177 178 179 181 182 184 185 187 188 190 191 193 194	<211 <211 <400 Met 1 Gly Glu Thr His 65 Ile	1> Li 2> Ti 3> Oi 0> Si Lys Ser Ser Val 50 Arg	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn Ile	H: 20 PRT ISM: ICE: Leu Arg 20 Glu Leu Cys	Oxyu 4 Gln 5 Ser Ala Glu Phe	Iranu Ile Cys Glu Ile Ser 70 Asp	Is mi Ile Glu Glu Ser 55 Ser Ser	Cys Ile Cys 40 Ser Ser	Pro Cys 25 Ala Ala Leu Val	Leu 10 His Ser Pro Cys Arg	Phe Asn Pro Ile Lys 75 Gly	Phe Glu Ser 60 Leu Arg	Gly Asp 45 Phe Glu Ile	Lys 30 Gln Arg His	15 Asp Cys Ser Phe Cys 95	Cys Gly Ile Asp 80 Cys	
170 172 173 174 175 177 178 179 181 182 184 185 187 191 193 194 196	<211 <211 <400 Met 1 Gly Glu Thr His 65 Ile	1> Li 2> Ti 3> Oi 0> Si Lys Ser Ser Val 50 Arg	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn Ile	H: 20 PRT ISM: ICE: Leu Arg 20 Glu Leu Cys Gly Arg	Oxyu 4 Gln 5 Ser Ala Glu Phe	Iranu Ile Cys Glu Ile Ser 70 Asp	Is mi Ile Glu Glu Ser 55 Ser Ser	Cys Ile Cys 40 Ser Ser	Pro Cys 25 Ala Ala Leu Val	Leu 10 His Ser Pro Cys Arg	Phe Asn Pro Ile Lys 75 Gly	Phe Glu Ser 60 Leu Arg	Gly Asp 45 Phe Glu Ile	Lys 30 Gln Arg His	15 Asp Cys Ser Phe Cys 95	Cys Gly Ile Asp 80 Cys	
170 172 173 174 175 177 178 179 181 182 184 185 187 191 193 194 196 197	<211 <212 <400 Met 1 Gly Glu Thr His 65 Ile Asp	1> L1 2> TY 3> OF 3> OF 1> SE 1 Lys Ser Val 50 Arg Asn Glu	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn Ile Glu	H: 20 PRT ISM: ICE: Leu Arg 20 Glu Leu Cys Gly Arg 100	Oxyu 4 Gln 5 Ser Ala Glu Phe His 85 Cys	Iranu Ile Cys Glu Ile Ser 70 Asp	Is mi Ile Glu Glu Ser 55 Ser Ser	Cys Ile Cys 40 Ser Ser Tyr	Pro Cys 25 Ala Ala Leu Val Gln 105	Leu 10 His Ser Pro Cys Arg 90 Phe	Phe Asn Pro Ile Lys 75 Gly	Phe Glu Ser 60 Leu Arg	Gly Asp 45 Phe Glu Ile Leu	Lys 30 Gln Arg His His	15 Asp Cys Ser Phe Cys 95 Leu	Cys Gly Ile Asp 80 Cys Ser	
170 172 173 174 175 177 178 179 181 182 184 185 187 191 193 194 196 197	<211 <212 <400 Met 1 Gly Glu Thr His 65 Ile Asp	1> L1 2> TY 3> OF 3> OF 1> SE 1 Lys Ser Val 50 Arg Asn Glu	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn Ile Glu Asn	H: 20 PRT ISM: ICE: Leu Arg 20 Glu Leu Cys Gly Arg 100	Oxyu 4 Gln 5 Ser Ala Glu Phe	Iranu Ile Cys Glu Ile Ser 70 Asp	Is mi Ile Glu Glu Ser 55 Ser Ser	Cys Ile Cys 40 Ser Fro	Pro Cys 25 Ala Ala Leu Val Gln 105	Leu 10 His Ser Pro Cys Arg 90 Phe	Phe Asn Pro Ile Lys 75 Gly	Phe Glu Ser 60 Leu Arg	Gly Asp 45 Phe Glu Ile Leu Ala	Lys 30 Gln Arg His His	15 Asp Cys Ser Phe Cys 95 Leu	Cys Gly Ile Asp 80 Cys Ser	
170 172 173 174 175 177 178 179 181 182 184 185 187 191 193 194 196 197 199 200	<211 <211 <400 Met 1 Gly Glu Thr His 65 Ile Asp	1> Li 2> TY 3> OI 0> SI Lys Ser Ser Val 50 Arg Asn Glu	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn Ile Glu Asn 115	PRT ISM: ISM: ICE: Leu Arg 20 Glu Leu Cys Gly Arg 100 Gly	Oxyu 4 Gln 5 Ser Ala Glu Phe His 85 Cys	Ile Cys Glu Ile Ser 70 Asp Glu His	Ile Glu Glu Ser 55 Ser Ser Ala Cys	Cys Ile Cys 40 Ser Tyr Gln Pro	Pro Cys 25 Ala Ala Leu Val Gln 105 Gly	Leu 10 His Ser Pro Cys Arg 90 Phe	Phe Asn Pro Ile Lys 75 Gly Pro Leu	Phe Glu Ser 60 Leu Arg Gly	Gly Asp 45 Phe Glu Ile Leu Ala 125	Lys 30 Gln Arg His Pis Pro 110 Phe	15 Asp Cys Ser Phe Cys 95 Leu Ser	Cys Gly Ile Asp 80 Cys Ser Val	
170 172 173 174 175 177 178 179 181 182 184 185 187 198 191 193 194 196 197 199 200 202	<211 <211 <400 Met 1 Gly Glu Thr His 65 Ile Asp	1> L1 2> TY 3> OF 3> OF 1> SI 2> TY 3> OF 2> SI 3> OF 3 OF 3> OF 3 OF 3> OF 3 OF 3> OF 3> OF 3> OF 3 OF	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn Ile Glu Asn 115	PRT ISM: ISM: ICE: Leu Arg 20 Glu Leu Cys Gly Arg 100 Gly	Oxyu 4 Gln 5 Ser Ala Glu Phe His 85 Cys	Ile Cys Glu Ile Ser 70 Asp Glu His	Is mile Glu Glu Ser Ser Ala Cys	Cys Ile Cys 40 Ser Tyr Gln Pro	Pro Cys 25 Ala Ala Leu Val Gln 105 Gly	Leu 10 His Ser Pro Cys Arg 90 Phe	Phe Asn Pro Ile Lys 75 Gly Pro Leu	Phe Glu Ser 60 Leu Arg Gly Gly Thr	Gly Asp 45 Phe Glu Ile Leu Ala 125	Lys 30 Gln Arg His Pis Pro 110 Phe	15 Asp Cys Ser Phe Cys 95 Leu Ser	Cys Gly Ile Asp 80 Cys Ser Val	
170 172 173 174 175 177 178 179 181 182 184 185 187 191 193 194 196 197 199 200	<211 <211 <400 Met 1 Gly Glu Thr His 65 Ile Asp	1> Li 2> TY 3> OI 0> SI Lys Ser Ser Val 50 Arg Asn Glu	EQ II ENGTH YPE: RGANI EQUEN Ser Cys Glu 35 Leu Asn Ile Glu Asn 115	PRT ISM: ISM: ICE: Leu Arg 20 Glu Leu Cys Gly Arg 100 Gly	Oxyu 4 Gln 5 Ser Ala Glu Phe His 85 Cys	Ile Cys Glu Ile Ser 70 Asp Glu His	Ile Glu Glu Ser 55 Ser Ser Ala Cys	Cys Ile Cys 40 Ser Tyr Gln Pro	Pro Cys 25 Ala Ala Leu Val Gln 105 Gly	Leu 10 His Ser Pro Cys Arg 90 Phe	Phe Asn Pro Ile Lys 75 Gly Pro Leu	Phe Glu Ser 60 Leu Arg Gly	Gly Asp 45 Phe Glu Ile Leu Ala 125	Lys 30 Gln Arg His Pis Pro 110 Phe	15 Asp Cys Ser Phe Cys 95 Leu Ser	Cys Gly Ile Asp 80 Cys Ser Val	

RAW SEQUENCE ISTING

PATENT APPLICATION: US/09/831,744

DATE: 03/21/2002 TIME: 18:35:51

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\03212002\1831744.raw

205 Ile Asn Leu Ala Gly Phe Arg Lys Glu Arg Tyr Pro Val Asp Ile Ala 150 155 208 Tyr Asn Ile Lys Gly Cys Thr Ser Ser Cys Pro Glu Leu Lys Leu Ser 165 170 211 Asn Arg Thr His Glu Glu Arg Arg Asn Asp Leu Ile Thr Leu Glu Cys 180 185 190 212 214 Thr Asp Ala Ser Lys Ile Thr Pro Ser Glu 195 217 <210> SEQ ID NO: 5 218 <211> LENGTH: 28 219 <212> TYPE: PRT 220 <213> ORGANISM: Notechis scutatus 222 <220> FEATURE: 223 <221> NAME/KEY: misc_feature 224 <222> LOCATION: (16)..(16) 225 <223> OTHER INFORMATION: X = any amino acid 227 <400> SEQUENCE: 5 228 Leu Glu Cys Glu Ile Cys Ile Gly Leu Gly Leu Glu Cys Asn Thr Xaa 229 1 5 231 Thr Lys Thr Cys Asp Ala Asn Gln Asp Thr Cys Val 20 25 234 <210> SEQ ID NO: 6 235 <211> LENGTH: 14 236 <212> TYPE: PRT 237 <213> ORGANISM: Notechis scutatus 239 <400> SEQUENCE: 6 240 Leu Glu Cys Glu Ile Cys Ile Gly Leu Gly Leu Glu Cys Asn 241 1 243 <210> SEQ ID NO: 7 244 <211> LENGTH: 5 245 <212> TYPE: PRT 246 <213> ORGANISM: Notechis scutatus 248 <400> SEQUENCE: 7 249 Ala Leu Ser Tyr Lys 250 1 252 <210> SEO ID NO: 8 253 <211> LENGTH: 19 254 <212> TYPE: PRT 255 <213> ORGANISM: Notechis scutatus 257 <400> SEQUENCE: 8 258 Ser Cys Gly Thr Ser Asp Thr Cys His Leu Asn Tyr Val Glu Thr Thr 259 1 261 Pro His Asn 263 <210> SEQ ID NO: 9 264 <211> LENGTH: 18 265 <212> TYPE: PRT 266 <213> ORGANISM: Notechis scutatus 268 <400> SEQUENCE: 9 269 Thr Cys Asp Ala Asn Gln Asp Thr Cys Val Thr Phe Gln Thr Glu Val

RAW SEQUENCE ISTING

DATE: 03/21/2002 TIME: 18:35:51

PATENT APPLICATION: US/09/831,744

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\03212002\1831744.raw

```
270 1
                                         10
                                                              15
272 Ile Arg
274 <210> SEQ ID NO: 10
275 <211> LENGTH: 8
276 <212> TYPE: PRT
277 <213> ORGANISM: Notechis scutatus
279 <400> SEQUENCE: 10
280 Ala Pro Val Thr Leu Gly Leu Ile
281 1
283 <210> SEQ ID NO: 11
284 <211> LENGTH: 10
285 <212> TYPE: PRT
286 <213> ORGANISM: Notechis scutatus
288 <400> SEQUENCE: 11
289 Glu Cys Thr Glu His Leu Val Ser Cys Arg
290 1
                    5
292 <210> SEQ ID NO: 12
293 <211> LENGTH: 13
294 <212> TYPE: PRT
295 <213> ORGANISM: Notechis scutatus
297 <400> SEQUENCE: 12
298 Phe Trp Asn Val Leu Glu Asp Val Glu Val Asp Phe Lys
299 1
301 <210> SEQ ID NO: 13
302 <211> LENGTH: 29
303 <212> TYPE: PRT
304 <213> ORGANISM: Notechis ater
306 <400> SEQUENCE: 13
307 His Ser Cys Glu Ile Cys His Asn Phe Gly Arg Asp Cys Gln Ser Asp
308 1
310 Glu Ala Glu Glu Cys Ala Ser Pro Glu Asp Gln Cys Gly
311
                20
313 <210> SEQ ID NO: 14
314 <211> LENGTH: 29
315 <212> TYPE: PRT
316 <213> ORGANISM: Notechis ater
318 <400> SEQUENCE: 14
319 His Ser Cys Glu Ile Cys His Asn Leu Gly Lys Asp Cys Glu Thr Glu
320 1
322 Glu Thr Glu Glu Cys Ala Ser Pro Glu Asp Gln Cys Gly
323
                20
                                     25
325 <210> SEQ ID NO: 15
326 <211> LENGTH: 5
327 <212> TYPE: PRT
328 <213> ORGANISM: Notechis ater
330 <400> SEQUENCE: 15
331 Ile Thr Pro Ser Glu
332 1
334 <210> SEQ ID NO: 16
```



Pulog

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/831,744

DATE: 03/13/2002

TIME: 15:12:52

Input Set : A:\13030.SEQ.txt

Output Set: N:\CRF3\03132002\I831744.raw

Does Not Comply Corrected Diskette Needed

3 <110> APPLICANT: Analytica Ltd

5 <120> TITLE OF INVENTION: PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER

7 <130> FILE REFERENCE: 2404732/EJH

9 <140> CURRENT APPLICATION NUMBER: US 09/831,744

C) > 10 <141> CURRENT FILING DATE: 2002-01-25

12 <150> PRIOR APPLICATION NUMBER: US 60/108,254

13 <151> PRIOR FILING DATE: 1998-11-12

15 <160> NUMBER OF SEQ ID NOS: 45

17 <170> SOFTWARE: PatentIn version 3.0

ERRORED SEQUENCES

775 <210> SEQ ID NO: 45

776 <211> LENGTH: 57

777 <212> TYPE: DNA

778 <213> ORGANISM: Notechis ater

781 <400> SEQUENCE: 45

782 algaaatccc tacagatcat ctgtcttctt ttcgttttgg tagccagagg aagctgt 57

E--> 794 (1)

VERIFICATION PATENT APPLICATION: US/09/831,744

03/13/2002 TIME: 15:12:53

Input Set : A:\13030.SEQ.txt

Output Set: N:\CRF3\03132002\1831744.raw .

L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:228 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 L:794 M:254 E: No. of Bases conflict, LENGTH:Input:1 Counted:57 SEQ:45

$\frac{1}{10000000000000000000000000000000000$		Editey:	sing Date: 3/2
Changed a file from non-ASCII to	ASCII ENTE	Verlified by:	(5
Changed the margins in cases who	ere the sequence text	was wapped down to the	e next line.
Edited a format error in the Curren	nt Application Data sect	ion, specifically:	
Edited the Current Application Data applicant was the prior applica	a section with the actual ation data; or other	al current number. The nu	mber inputted b
Added the mandatory heading and	d subheadings for "Cum	ent Application Data*.	. •
Edited the "Number of Sequences"	field. The applicant sp	pelled out a number instea	ad of using an in
Changed the spelling of a mandato	ory field (the headings o	or subheadings), specifica	lly:
Corrected the SEQ ID NO when ob	bviously incorrect. The	sequence numbers that w	vere edited were
nserted or corrected a nucleic num	nber at the end of a nuc	cleic line. SEQ ID NO's e	dited:
Corrected subheading placement. applicant placed a response below	All responses must be the subheading, this w	on the same line as each as moved to its appropria	subheading. If the place.
Inserted colons after headings/sub	oheadings. Headings e	dited included:	
Deleted extra, invalid, headings us	sed by an applicant, spe	ecifically:	
Deleted: non-ASCII "garbage" page numbers throughout tex	' at the beginning/end o	f files; secretary initia	uls/filename at er
Inserted mandatory headings, spe	ecifically:		
Corrected an obvious error in the	response, specifically:		,
Edited identifiers where upper cas	se is used but lower cas	e is required, or vice versa	a.
Corrected an error in the Number	of Sequences field, spe	xifically:	
A "Hard Page Break" code was ins			
Deleted <i>ending</i> stop codon in amir due to a Patentin bug). Sequences	no acid sequences and scorrected:	adjusted the *(A)Length:*	field accordingly
Other:			

^{*}Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.